Merck Competitive Intelligence & Landscape

Merck (merck.com) is a global research-intensive biopharmaceutical company dedicated to inventing and delivering innovative health solutions. Established on January 1, 1891, by George Merck in the U.S., the company has a long history of developing significant medicines and vaccines, guided by the belief that such innovations can change the world [https://www.merck.com/company-overview/history/]. Its mission is to save and improve lives globally, a principle that underpins its leadership and operations [https://www.merck.com/company-overview/leadership/].

Merck provides prescription medicines, vaccines, biologic therapies, and animal health products, serving a broad target market that includes patients, investors, and communities worldwide [https://www.merck.com/media/company-fact-sheet/]. The company’s focus areas in research include oncology, vaccines, infectious diseases, cardiometabolic and respiratory diseases, immunology, neuroscience, and ophthalmology. They also explore areas of innovation such as data science, artificial intelligence, green and sustainable science, and translational medicine [https://www.merck.com/].

Headquartered in Rahway, New Jersey, USA, at 126 East Lincoln Avenue, Merck is known as Merck in the United States and Canada, and MSD outside these regions [https://www.merck.com/investor-relations/investor-resources/]. The company is publicly traded on the New York Stock Exchange (NYSE) under the ticker symbol “MRK” [https://www.merck.com/wp-content/uploads/sites/124/2025/02/0001628280-25-007732.pdf]. With worldwide sales of $64.2 billion, Merck is a significant player in the global healthcare industry [https://www.merck.com/investor-relations/].

Merck is committed to sustainability and operates responsibly to enable a safe and healthy future for people and communities globally. The company also maintains transparency disclosures and various sustainability resources [https://www.merck.com/]. Their corporate governance is essential to serving patients and achieving long-term shareholder value, reflecting a commitment to policies and practices that benefit all stakeholders [https://www.merck.com/company-overview/leadership/].

Merck (merck.com) offers various medicines and vaccines, including products like ANTIVENIN™, BCG Vaccine, BELSOMRA®, and CANCIDAS® [https://www.merck.com/products/]. The company emphasizes making its products accessible and affordable through responsible pricing and patient access programs [https://www.merck.com/wp-content/uploads/sites/124/2024/02/PricingAction_TransparencyReport_2023.pdf].

Merck has a commitment to not increase the average net price across its product portfolio by more than inflation annually [https://www.merck.com/news/merck-reinforces-commitment-to-responsible-pricing/]. In 2023, the average annual net price increase for their portfolio was 4.4%, while the average annual list price increased by 4% [https://www.merck.com/wp-content/uploads/sites/124/2024/02/PricingAction_TransparencyReport_2023.pdf]. The company also provides transparency in coverage information regarding its health plan's pricing [https://www.merck.com/what-we-do/].

For eligible patients, Merck offers Patient Assistance Programs that provide certain medicines and adult vaccines for free [https://www.merck.com/merckhelps/]. These programs are designed to help individuals without prescription drug or health insurance coverage [https://www.merck.com/merckhelps/] and are free of charge to those who qualify [https://www.merck.com/merckhelps/patientassistance/contact.html]. Furthermore, Merck is expanding access to medicines and lowering costs for Americans through a direct-to-patient program offering affordable prices for eligible patients in the U.S. [https://www.merck.com/news/merck-reaches-agreement-with-u-s-government-to-expand-access-to-medicines-and-lower-costs-for-americans/].

Merck (merck.com) actively seeks to expand its workforce across various critical divisions, reflecting its commitment to being a premier research-intensive biopharmaceutical company. The company’s careers site [jobs.merck.com/us/en] highlights numerous current job opportunities, inviting individuals to join its mission of saving and improving lives.

Merck shows a strong focus on scientific and technical roles, with dedicated career pages for Research & Development [jobs.merck.com/us/en/research-laboratories], Manufacturing & Supply [jobs.merck.com/us/en/manufacturing], and Information Technology [jobs.merck.com/us/en/information-technology]. Specifically, there's a demand for roles in Data & Advanced Analytics [jobs.merck.com/us/en/data-advanced-analytics], including Data Scientists, Analytics Leads, Data Engineers, and Data Analysts. The company also offers Skills-First Opportunities [jobs.merck.com/us/en/skills-first-opportunities] in locations like Elkton, VA, Elkhorn, NE, Durham, NC, and West Point, PA, which include positions such as Maintenance Technician [jobs.merck.com/us/en/search-results].

Merck's hiring patterns indicate a strategic push towards innovation and operational excellence. The company is particularly interested in clinical roles, as evidenced by its

Merck (merck.com) demonstrates robust financial performance, as evidenced by its strong sales figures. The company reported worldwide sales of $16.3 billion in the first quarter of 2026, marking a 5% growth [merck.com/news/merck-co-inc-rahway-n-j-usa-announces-first-quarter-2026-financial-results-highlights-significant-regulatory-approvals-and-clinical-milestones/]. This follows a successful 2025, where Merck achieved $16.4 billion in worldwide sales for the fourth quarter and a full-year total of $65.0 billion [merck.com/stories/our-q4-and-full-year-2025-financial-results/]. These financial results highlight the company's continued strength, particularly in oncology and animal health, and increasing contributions from new product launches [merck.com/stories/our-q1-2026-financial-results/].

The company is actively transforming its portfolio to include a diversified set of growth drivers across various therapeutic areas, as stated by Rob Davis, chairman and CEO [merck.com/stories/our-q1-2026-financial-results/]. Key products like KEYTRUDA and KEYTRUDA QLEX contributed significantly to sales, reaching $8.0 billion in Q1 2026 with 12% growth. Additionally, WINREVAIR sales saw substantial growth at $525 million, an 88% increase in the same period [merck.com/news/merck-co-inc-rahway-n-j-usa-announces-first-quarter-2026-financial-results-highlights-significant-regulatory-approvals-and-clinical-milestones/].

Merck is known as a premier research-intensive biopharmaceutical company [merck.com/investor-relations/financial-information/].

Merck provides extensive financial information for investors, including quarterly and annual reports, and SEC filings, which are accessible on its investor relations page [merck.com/investor-relations/financial-information/] [merck.com/investor-relations/financial-information/sec-filings/]. The company's ticker symbol is MRK [merck.com/media/company-fact-sheet/].

Merck's commitment to financial transparency is evident in its detailed reporting, including disclosures on costs, expenses, and other income/loss before taxes [merck.com/wp-content/uploads/sites/124/2026/04/1Q26-Merck-Other-Financial-Disclosures.pdf].

Merck (merck.com) actively engages in various investor and healthcare conferences, showcasing its leadership and research advancements. The company plans to host an Investor Event at ASCO 2026 in Chicago, IL on June 1, 2026, and an HIV Investor Event on July 17, 2025, demonstrating its commitment to specific therapeutic areas and investor communication https://www.merck.com/events/investor-event-at-asco-2026/ https://www.merck.com/events/hiv-investor-event/.

Merck also has a consistent presence at significant financial and healthcare conferences. Robert M. Davis, chairman and chief executive officer, and Dr. Dean Y. Li, executive vice president and president, Merck Research Laboratories, are scheduled to participate in the Goldman Sachs 47th Annual Global Healthcare Conference https://www.merck.com/news/merck-to-participate-in-the-goldman-sachs-47th-annual-global-healthcare-conference/. Additionally, Merck will participate in the Jefferies Global Healthcare Conference, with Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, attending https://www.merck.com/news/merck-to-participate-in-the-jefferies-global-healthcare-conference/.

Further demonstrating its engagement with the investment community, Merck will participate in the TD Cowen 46th Annual Health Care Conference, featuring Caroline Litchfield, executive vice president and chief financial officer, and Dr. Dean Y. Li https://www.merck.com/news/merck-to-participate-in-the-td-cowen-46th-annual-health-care-conference/. The company will also be present at the 2025 Wells Fargo Healthcare Conference on September 4, 2025 https://www.merck.com/events/2025-wells-fargo-healthcare-conference/. These events provide platforms for Merck to share its financial performance and strategic outlook.

Beyond investor events, Merck actively participates in scientific gatherings like ASCO 2026, where it highlights new long-term data and advancements across its oncology portfolio and pipeline research, presenting over 100 abstracts on more than 25 types of cancer https://www.merck.com/news/merck-highlights-new-long-term-data-and-advancements-across-broad-oncology-portfolio-and-pipeline-research-at-asco-2026/.

Merck also conducts internal investor-focused events such as its Q2 2026 Earnings Call on August 4, 2026, and its 2026 Annual Meeting of Shareholders on May 26, 2026, to communicate directly with its investors https://www.merck.com/events/q2-2026-earnings-call/ https://www.merck.com/events/2026-annual-meeting-of-shareholders/.